McKesson Raises Guidance After Q3 Earnings, Sees 17-19% YoY EPS Growth

McKesson reported Q3 consolidated revenue of $106.2 billion, up 11% YoY, with double-digit adjusted EPS growth. Growth was driven by specialty and biopharma, with Oncology & Multispecialty revenue rising 37% to $13 billion and GLP-1 distribution reaching $14 billion, up 26%. The company raised full-year EPS guidance to $38.80-$39.20 and plans to return $2.5 billion of repurchases for fiscal 2026.